User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

4207

Interactions with Platform & by Email *

INTERACTIONS

757

Unique # Participated *

PARTICIPANTS

126

Responses Validated *

VALIDATIONS

36

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Irritable Bowel Syndrome: A Primer.....II-4
Market Analysis.....II-4
World IBS Market to Witness Substantial Growth Despite of Anticipated Slump in the GI Therapeutics Market.....II-4
1$100
   New Drug Launches to Drive the Growth of Highly Underserved IBS Market in Developed Markets.....II-5
Select Drugs in Late Stage Clinical Development.....II-5
1$100
   Linaclotide: One of the Most Promising Pipeline Drugs with Substantial Market Potential.....II-6
Irritable Bowel Syndrome Represents a Major Therapeutic Challenge.....II-6
Available IBS Drugs: Treating the Symptoms, Not the Cause.....II-6
A Comparison of Current and Previous Treatment for IBS.....II-6
1$100
   Select Drugs/Therapeutics Available for IBS Treatment by Symptom.....II-7
Involvement of the Brain-Gut Axis Emphasized the Role of Serotonin in IBS.....II-7
Serotonin 5-HT Receptors Led the Drug Development Pipeline.....II-7
Lack of Selectivity Hampers Predominance of 5-HT Receptor Class of Drugs.....II-7
1$100
   List of 5-HT Class Drug Withdrawals/ Trial Failures.....II-8
Amitiza Led the IBS-C Market in 2008-2009, New Drug Launches Likely to Affect Sales.....II-8
Safety Concerns of Available Drugs and Low Rate of Diagnosis Limit Market Growth.....II-8
1$100
   Growth Drivers.....II-9
IBS Market is Presently Highly Fragmented, Generecized, and Under Served.....II-9
Drug Development Programs Drive Market Growth in Developed Countries.....II-9
1$100
   Product Co-development, Commercialization, and Licensing Agreements.....II-10
Other Growth Drivers.....II-10
High Prevalence.....II-10
1$100
   Variable Diagnostic Criteria and IBS Prevalence.....II-11
Growing Awareness.....II-11
Multiple Treatment Approaches Make Way for Complementary Medicines.....II-11
1$100
   Need for Diagnostic Markers.....II-12
Development of Novel Therapies.....II-12
1$100
   Prevalence.....II-13 1$100
   Table 1: Prevalence of IBS in Select Countries/ Regions of the World (includes corresponding Graph/Chart).....II-14
Prevalence by Gender: Higher Prevalence in Women.....II-14
1$350
   Symptoms of IBS.....II-15
Comorbidities Associated with IBS.....II-15
Classification of IBS Based on Symptoms.....II-15
1$100
   Diarrhea-predominant IBS or IBS-D.....II-16
Constipation-predominant IBS or IBS-C.....II-16
Alternating or Mixed Type IBS.....II-16
List of Select Conditions that could be Misdiagnosed as IBS.....II-16
Select Tests Recommended to Rule out GI Disorders Other than IBS.....II-16
What Causes Irritable Bowel Syndrome.....II-16
The Function of the Colon.....II-16
1$100
   IBS and the Enteric Nervous System.....II-17
The Brain-Gut Interaction.....II-17
Direct Control.....II-17
1$100
   Indirect Control.....II-18
Etiology of Irritable Bowel Syndrome.....II-18
Chronic Anxiety Mediated Visceral Hyperalgesia.....II-18
Serotonin.....II-18
1$100
   5HT3 and 5HT4 Receptors.....II-19
Genetic Factors.....II-19
Gastrointestinal Infections.....II-19
The Intestinal Bacteria.....II-19
1$100
   Diagnosis of Irritable Bowel Syndrome.....II-20
IBS Diagnostic Protocols.....II-20
The Rome III Criteria for IBS Diagnosis.....II-20
1$100
   IBS Diagnosis in Children.....II-21
The Manning Criteria for IBS Diagnosis.....II-21
1$100
   Current Treatment Scenario.....II-22
Combination Therapies Offer Limited Efficacy and Short-Term Relief.....II-22
1$100
   An Overview of Select Treatment and Therapies for Irritable Bowel Syndrome.....II-23
Select Drug Classes Available for IBS Treatment.....II-23
Dietary Fiber.....II-23
List of Select Commercially Packaged Fibers.....II-23
Bulk-forming Laxatives.....II-23
1$100
   Osmotic laxatives.....II-24
List of Select Osmotic Laxatives.....II-24
Poorly Absorbed Ions.....II-24
Poorly Absorbed Sugars.....II-24
Stimulant laxatives.....II-24
1$100
   List of Select Stimulant Laxatives by Type.....II-25
Derivatives of Diphenylmethane.....II-25
Derivatives of Anthraquinones.....II-25
Emollients.....II-25
Anti-Diarrheals.....II-25
1$100
   Antidepressants.....II-26
Scientific Data Supports the Use of Antidepressants in IBS.....II-26
Tricyclics: Preferred Class of Antidepressants for Treating IBS.....II-26
1$100
   Side Effects of TCAs.....II-27
Antispasmodic Agents.....II-27
Anticholinergic Agents.....II-27
1$100
   List of Select Anticholionergics.....II-28
Peppermint Oil and Direct Smooth Muscle Relaxants.....II-28
List of Select Direct Smooth Muscle Relaxants.....II-28
1$100
   Alternative Therapies.....II-29
Probiotics.....II-29
What are probiotics?.....II-29
Role of Probiotics.....II-29
Potential Use of Probiotics in IBS Management.....II-29
Data from Research and Clinical Studies.....II-29
Herbal Remedies.....II-29
1$100
   Psychotherapy.....II-30
Others.....II-30
1$100
   Lotronex.....II-31
Zelnorm.....II-31
Amitiza.....II-31
1$100
   BENTYL® (dicyclomine hydrochloride).....II-32
Colpermin.....II-32
1$100
   Irribow (Ramosetron Hydrochloride).....II-331$100
   Linaclotide.....II-34
LX1031.....II-34
XIFAXAN® (Rifaximin).....II-34
ASIMADOLINE.....II-34
1$100
   Drugs’ Early Stage Clinical Trials.....II-35
Select IBS Drugs in Early Stages of Clinical Trials.....II-35
1$100
   Review of Pipeline Drugs in the Past (2006).....II-361$100
   Synergy Pharmaceuticals to Conduct Phase II/III Trial of Plecanatide.....II-37
Almirall and Ironwood Achieve Success in Second Phase III Trial of Linaclotide in IBS-C.....II-37
1$100
   Oxy-Powder Demonstrates Success in IBS Test.....II-38
Ironwood and Forest Achieve Positive Results in Phase 3 Trial of Linaclotide.....II-38
VSL 3 Proves Effective for Children Suffering from IBS.....II-38
Salix’s Xifaxan (Rifaximin) Found Effective on Non-C IBS Symptom.....II-38
1$100
   Lexicon Concludes Phase II Clinical Trial of LX1031.....II-39
Ocera Achieves Positive Result in Phase 2 Proof-of- Concept Trial of AST-120.....II-39
1$100
   Pharmos Achieves Positive Results in Phase 2b IBS Trial.....II-40
Order-Made Souyaku to Commence IBS Drug Trials in the UK.....II-40
1$100
   Tioga Receives Fast Track Status for Asimadoline in IBS-D.....II-41
Canadian Institut Rosell Extends Partnership with Probi.....II-41
Achieve Clinical Research Commences Clinical Trials for IBS.....II-41
1$100
   Wild Partners with Sterling Technology.....II-42
AMRI Proposes New Drug For Irritable Bowel Syndrome.....II-42
Salix Obtains FDA’s Filing and Priority Review Approval for XIFAXAN550 in Non-C IBS.....II-42
1$100
   Soligenix Receives US Patent for Beclomethasone Dipropionate for IBS Treatment.....II-43
Meda Takes Over Norgine’s Over-the-Counter Drugs.....II-43
Tioga Reaches Agreement with FDA For Phase 3 Trials Of Asimadoline.....II-43
Sucampo Files ‘Demand for Arbitration’ Against Takeda.....II-43
1$100
   Abbott Takes Over Solvay Pharmaceuticals.....II-44
SK Holdings Obtains IND Approval from FDA for YKP10811.....II-44
MicroDose Takes Over Epix’s Portfolio of Compounds.....II-44
1$100
   PPD Inks Agreement with Janssen Pharmaceutica.....II-45
Warner Chilcott Takes Over P&G’s Global Branded Prescription Pharmaceutical Business.....II-45
1$100
   Abbott Acquires Solvay’s Pharmaceutical Business.....II-46
Tioga and Ono Ink Licensing Agreement for IBS Drug Development.....II-46
Lexicon Reacquires Joint Venture Rights from Symphony.....II-46
Ironwood Enters into Partnership with Almirall.....II-46
1$100
   Pawfect Foods Takes Over Synergy Pharmaceuticals.....II-47
Tioga and US FDA Agree on SPA for Phase 3 Efficacy Protocols of Asimadoline in IBS-D.....II-47
1$100
   Sucampo Obtains FDA Approval for AMITIZA for IBS-C in Adult Women.....II-48
Apex and Dynogen Dissolve Merger Agreement.....II-48
1$100
   Rose Pharma and Eli Lily Ink Licensing Agreement Pertaining to Compound for IBS Treatment.....II-49
Napo and Trine Terminate License Agreement for Crofelemer.....II-49
1$100
   Cedars-Sinai Medical Center Introduces Rifaximin for IBS Patients.....II-50
Lesaffre Introduces Probiotic Yeast to Treat Intestinal Discomfort.....II-50
Lifeway Foods Launches BioKefir Range of Probiotic Drinks.....II-50
1$100
   Mayo Clinic Discovers Novel Genetic Variants in Serotonin Genes.....II-51
Jarrow Formulas® to Introduce Ideal Bowel Support 299v®.....II-51
Buscopan Launches Online Interactive Resource for IBS Patient.....II-51
Chongqing Fortune Introduces Traditional Chinese Medicine.....II-51
1$100
   Alimentary Health to Introduce New Probiotic Treatment.....II-52
Alimentary Health to Launch IBS Treatment.....II-52
Astellas Pharma Introduces Irribow for Irritable Bowel Syndrome.....II-52
1$100
   Abbott Laboratories (US).....II-53
Alimentary Health Limited (Ireland).....II-53
Edusa Pharmaceuticals (US).....II-53
Ironwood Pharmaceuticals, Inc. (US).....II-53
1$100
   Forest Laboratories, Inc. (US).....II-54
Lexicon Pharmaceuticals (US).....II-54
1$100
   Pharmos Corporation (US).....II-55
Salix Pharmaceuticals, Inc. (US).....II-55
1$100
   Sucampo Pharmaceuticals, Inc. (US).....II-56
Tioga Pharmaceuticals, Inc. (US).....II-56
1$100
   Table 2: World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) by Geographic Region - US, Japan, Europe, Rest of World Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-571$350
   Table 3: World Historic Review for Irritable Bowel Syndrome (IBS) by Geographic Region - US, Japan, Europe, and Rest of World Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-581$350
   Table 4: World 15-Year Perspective for Irritable Bowel Syndrome (IBS) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-591$350
   A. Market Analysis.....II-60
An Overview.....II-60
Prevalence of IBS-C in the US.....II-60
US Leads the Global IBS Drug Development Scenario.....II-60
High Unmet Needs Characterize the IBS Market.....II-60
1$100
   New Drugs Releases Likely to Drive Market Growth in the Near Future.....II-61
Irritable Bowel Syndrome: Key Facts.....II-61
Drugs Approved for Use in IBS Treatment.....II-61
Amitiza.....II-61
1$100
   Zelnorm.....II-62
Lotronex.....II-62
Strategic Corporate Developments.....II-62
7$225
   Product Introductions/Innovations.....II-692$125
   Focus on Select Major Players.....II-71
Abbott Laboratories (US).....II-71
Edusa Pharmaceuticals (US).....II-71
Ironwood Pharmaceuticals, Inc. (US).....II-71
1$100
   Forest Laboratories, Inc. (US).....II-72
Lexicon Pharmaceuticals (US).....II-72
Pharmos Corporation (US).....II-72
1$100
   Salix Pharmaceuticals, Inc. (US).....II-73
Sucampo Pharmaceuticals, Inc. (US).....II-73
1$100
   Tioga Pharmaceuticals, Inc. (US).....II-741$100
   B. Market Analytics.....II-75
Table 5: The US Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-75
1$350
   Table 6: The US Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-761$350
   A. Market Analysis.....II-77
Strategic Corporate Development.....II-77
Product Introductions/Innovation.....II-77
1$100
   B. Market Analytics.....II-78
Table 7: Japanese Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-78
1$350
   Table 8: Japanese Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-791$350
   Market Analysis.....II-80
Market Analysis.....II-80
1$100
   Table 9: European Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-811$350
   Table 10: European Historic Review for Irritable Bowel Syndrome (IBS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-821$350
   Table 11: European 15-Year Perspective for RNA Interference Application by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-831$350
   Market Analysis.....II-84
Table 12: French Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-84
1$350
   Table 13: French Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-851$350
   Market Analysis.....II-86
Table 14: German Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-86
1$350
   Table 15: German Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-871$350
   Market Analysis.....II-88
Table 16: Italian Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-88
1$350
   Table 17: Italian Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-891$350
   A. Market Analysis.....II-90
Product Introductions/Innovation.....II-90
B. Market Analytics.....II-90
Table 18: The UK Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-90
1$350
   Table 19: The UK Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-911$350
   A. Market Analysis.....II-92
Strategic Corporate Development.....II-92
1$100
   B. Market Analytics.....II-93
Table 20: Spanish Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-93
1$350
   Table 21: Spanish Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-941$350
   Market Analysis.....II-95
Table 22: Russian Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-95
1$350
   Table 23: Russian Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-961$350
   A. Market Analysis.....II-97
Strategic Corporate Developments.....II-97
1$100
   Product Introductions/Innovations.....II-981$100
   Focus on Select Key Player.....II-99
Alimentary Health Limited (Ireland).....II-99
B. Market Analytics.....II-99
Table 24: Rest of European Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-99
1$350
   Table 25: Rest of European Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1001$350
   A. Market Analysis.....II-101
Strategic Corporate Developments.....II-101
Product Introductions/Innovation.....II-101
1$100
   B. Market Analytics.....II-102
Table 26: Rest of World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-102
1$350
   Table 27: Rest of World Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1031$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com